Pfizer and Glenmark Pharmaceuticals Ltd. (Glenmark) have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.
The Indian launch of JABRYUS® and CIBINQO®, a groundbreaking treatment for moderate-to-severe AD, will be co-marketed by Glenmark and Pfizer, offering improved efficacy and oral convenience to patients. Abrocitinib (CIBINQO) is available in over 35 markets globally, including the U.S., Japan, and China. Atopic dermatitis is a chronic skin disease causing inflammation and skin barrier defects. Itching in moderate-to-severe AD disrupts daily life, impacting social interactions, work productivity, and overall well-being.
Abrocitinib, a Janus kinase 1 inhibitor, provides rapid itch relief, sustained disease control, and improved quality of life. Meenakshi Nevatia, Country President and Managing Director of Pfizer India stated, “Our collaboration with Glenmark will help leverage the collective strengths and capabilities of our organizations to make this breakthrough therapy available to patients and physicians across our country.”
